Drug Profile

YRA 1909

Alternative Names: YRA1909

Latest Information Update: 31 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yungjin Pharm Co
Class Antirheumatics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Rheumatoid arthritis

Most Recent Events

30 Sep 2020 YRA 1909 is still in phase II trials for Rheumatoid arthritis in South Korea (PO) (NCT03275025)
19 Nov 2019 Yungjin Pharm completes a phase II trial in Rheumatoid arthritis in South Korea (PO) (NCT03275025)
03 Nov 2017 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com